Ailawadhi S, Špička I, Spencer A, Lu J, Oriol A, Ling S, Schjesvold F, Berkovits A, Hus M, Li C, Dimopoulos MA, Rajnics P, Beşışık SK, Hungria V, Custidiano MDR, Parmar G, Leleu X, Li F, Cerchione C, Gomez C, Ishida T, Mateos MV, Buck TT, LeBlanc R, Minařík J et al. (2025)
Isatuximab Subcutaneous by On-Body Injector Versus Isatuximab Intravenous Plus Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Phase III IRAKLIA Study
J Clin Oncol, JCO2500744 (in press)
DOI 10.1200/JCO-25-00744, PubMed 40459178

Raab MS, Cohen YC, Schjesvold F, Aardalen K, Oka A, Spencer A, Wermke M, Souza AD, Kaufman JL, Cafro AM, Ocio EM, Doki N, Henson K, Trabucco G, Carrion A, Bender FC, Juif PE, Fessehatsion A, Fan L, Stonehouse JP, Blankenship JW, Granda B, De Vita S, Lu H (2025)
Correction: Preclinical discovery and initial clinical data of WVT078, a BCMA × CD3 bispecific antibody
Leukemia, 39 (6), 1545
DOI 10.1038/s41375-025-02516-7, PubMed 40374810

Rodriguez-Otero P, Voorhees PM, Boccadoro M, Laubach J, Einsele H, Sborov DW, Dimopoulos MA, Broijl A, Mina R, Spencer A, Schjesvold F, Silbermann R, Gay F, Costa LJ, Perrot A, Liu Y, Wang J, Sitthi-Amorn A, Carson R, Cortoos A, Usmani SZ, Richardson PG, Moreau P, Sonneveld P, Kaufman JL (2025)
Daratumumab for newly diagnosed multiple myeloma: Pooled analysis of patients aged ≥65 years from GRIFFIN and PERSEUS
Clin Lymphoma Myeloma Leuk (in press)
DOI 10.1016/j.clml.2025.04.007, PubMed 40360369